Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Keros Therapeutics Inc
KROS
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$11.40
0.34
3.07%
Últ. Act.: Oct 20, 5:00 PM
$11.40
0.34
3.07%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Keros Therapeutics Financials
Keros Therapeutics (KROS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Keros Therapeutics Q2 EPS $(1.45) Misses $(1.34) Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.45) per share which missed the analyst consensus estimate of $(1.34) by 8.21 percent. This is a 90.79 percent decrease over losses of $(0.76) per share
Benzinga Newsdesk
PRO
Keros Therapeutics Q1 EPS $(1.21) Misses $(1.02) Estimate, Sales $367.000K Miss $583.333K Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(1.21) per share which missed the analyst consensus estimate of $(1.02) by 18.63 percent. This is a 133.43 percent decrease over earnings of $3.62 per share
Benzinga Newsdesk
PRO
CORRECTION: Keros Therapeutics Q4 EPS $(0.86) Misses $(0.60) Estimate, Sales $385.000K Miss $2.757M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.60) by 42.62 percent. This is a 24.56 percent increase over losses of $(1.14) per share
Benzinga Newsdesk
Keros Therapeutics: Q4 Earnings Insights
Benzinga Insights
PRO
Keros Therapeutics Q3 EPS $(0.18) Beats $(1.05) Estimate, Sales $14.262M Beat $3.800M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(1.05) by 82.81 percent. This is a 87.23 percent increase over losses of $(1.41) per share
Benzinga Newsdesk
PRO
Keros Therapeutics Q2 EPS $(0.76) Beats $(1.11) Estimate, Sales $18.168M Beat $2.767M Estimate
Keros Therapeutics (NASDAQ:KROS) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(1.11) by 31.78 percent. This is a 39.2 percent increase over losses of $(1.25) per share from
Benzinga Newsdesk
